Green C P, Price J F
Department of Thoracic Medicine, King's College Hospital, London.
Arch Dis Child. 1992 Aug;67(8):1014-7. doi: 10.1136/adc.67.8.1014.
The effect of inhaled salmeterol xinafoate, a long acting beta 2 agonist, on exercise induced asthma was studied in a double blind, crossover, and placebo controlled trial. Thirteen asthmatic children with a fall of at least 15% in their forced expiratory volume in one second (FEV1) after a standard exercise test on a motorised treadmill, on separate days performed the same test 1, 5, and 9 hours after a single dose of 50 micrograms salmeterol or placebo. FEV1 was measured before treatment, and before and for 30 minutes after each exercise test. After placebo the number of children with exercise induced asthma was: 10 at 1 hour, 11 at 5 hours, and 12 at 9 hours. Salmeterol prevented exercise induced asthma in all 13 children studied, at 1, 5, and 9 hours. Mean maximum falls in FEV1 after exercise were at 1 hour: salmeterol 2.7% and placebo 24.6%, 5 hours: salmeterol 5.3% and placebo 22.7%; and 9 hours: salmeterol 3.4% and placebo 26.6%. After salmeterol the mean increase in FEV1 was 17.8% at 1 hour, 19.6% at 5 hours, and 19.2% at 9 hours. Inhaled salmeterol prevents exercise induced asthma and produces significant bronchodilatation for at least 9 hours.
在一项双盲、交叉且安慰剂对照试验中，研究了长效β2受体激动剂昔萘酸沙美特罗吸入剂对运动诱发性哮喘的影响。13名哮喘儿童在电动跑步机上进行标准运动试验后，一秒用力呼气量（FEV1）至少下降15%。在不同日期，他们在单剂量50微克沙美特罗或安慰剂给药后1、5和9小时分别进行相同试验。在每次治疗前、每次运动试验前及试验后30分钟测量FEV1。使用安慰剂后，运动诱发性哮喘患儿数量分别为：1小时10例，5小时11例，9小时12例。沙美特罗可在给药后1、5和9小时预防所有13名受试患儿的运动诱发性哮喘。运动后FEV1的平均最大下降幅度为：1小时，沙美特罗组为2.7%，安慰剂组为24.6%；5小时，沙美特罗组为5.3%，安慰剂组为22.7%；9小时，沙美特罗组为3.4%，安慰剂组为26.6%。使用沙美特罗后，FEV1在1小时平均增加17.8%，5小时增加19.6%，9小时增加19.2%。吸入沙美特罗可预防运动诱发性哮喘，并产生显著的支气管扩张作用，且至少持续9小时。
